In a phase 1 trial for a DNA vaccine encoding HER-2/neu for advanced-stage ERBB2-positive breast cancer (NCT00436254), participants aged 34–77 years were immunized three times with one of three dosages (50, 100, or 500ug) (160). This evidence concerns the gene ERBB2 and breast carcinoma.